FDA Approves Companion Test to Identify Patients Eligible for New NSCLC Treatment
The test is approved to identify patients eligible for Hernexeos, an orally administered targeted treatment for HER2 (ERBB2)-mutant non-small cell lung cancer.
The test is approved to identify patients eligible for Hernexeos, an orally administered targeted treatment for HER2 (ERBB2)-mutant non-small cell lung cancer.
Thermo Fisher Scientific has launched the One Lambda HybriType HLA Plus Typing Flex kit, an NGS hybrid capture assay.
OGT's SureSeq Myeloid MRD Panel offers a NGS solution for ultra-sensitive detection of MRD biomarkers in acute myeloid leukemia.
Illumina’s new MiSeq i100 Series sequencing systems provide faster, simpler, and more cost-efficient next-generation sequencing solutions.
Read MoreReducing the incidence of healthcare-associated infections, and the antimicrobial resistance they can trigger, is critical for patient care.
Read MoreThe next-generation sequencing assay delivers rapid and comprehensive genetic profiling for AML patients, guiding precise treatment decisions.
Read MoreA new study emphasizes the potential of advanced sequencing techniques in improving outcomes for CRC patients with rare genetic variants.
Read MoreAmbry Genetics unveiled a new multiomic exome sequencing test that incorporates RNA analysis to enhance the detection of rare diseases.
Read MoreGeneDx announced enhancements to its whole genome sequencing services, all aimed at accelerating diagnoses and improving health outcomes.
Read MoreBaylor Genetics and Baylor College of Medicine have launched the Medical Genetics Multi-Omics Laboratory to innovate genetic testing.
Read MoreThe Unlock Behind the Seizure program aims to provide accessible and affordable genetic testing for pediatric epilepsy patients.
Read MoreWhole genome sequencing has improved care for some children with cancer in England and can potentially replace multiple standard tests.
Read MoreA new genotyping test using cerebrospinal fluid can rapidly diagnose brain cancers, reducing the need for invasive biopsies.
Read MoreFoundation Medicine launched a tissue-based RNA sequencing test in the U.S. for the detection of cancer-related fusions across 318 genes.Â
Read MoreJona announced a new distribution partnership where practitioners can order Jona kits, the company’s AI-powered gut microbiome profile test.
Read MoreResearchers developed a urine-based test utilizing whole genome sequencing to detect DNA fragments released by head and neck tumors.
Read MoreThe collaboration seeks to demonstrate the value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
Read MoreResearchers developed a platform for integrating DNA and RNA data from single-cell sequencing with improved speed and precision.
Read More